Vepdegestrant在雌激素受体阳性乳腺癌试验中显示出适度的无进展生存改善-动脉网

Vepdegestrant Shows Modest Progression-Free Survival Improvement in Estrogen Receptor-Positive Breast Cancer Trials

GeneOnline 等信源发布 2025-05-31 21:04



可切换为仅中文







by Mark Chiang

马克·蒋

Share To

分享到

Arvinas and Pfizer have released detailed clinical trial results for vepdegestrant, a drug developed using their proprietary “Protac” technology, aimed at treating breast cancer. The findings indicate that vepdegestrant demonstrated improved outcomes compared to a standard treatment option in a specific subset of patients.

Arvinas 和辉瑞发布了使用其专有的“Protac”技术开发的药物 vepdegestrant 的详细临床试验结果，该药物旨在治疗乳腺癌。研究结果显示，在特定患者子集中，vepdegestrant 相较于标准治疗方案表现出更好的疗效。

However, the improvement in progression-free survival was described as modest..

然而，无进展生存期的改善被描述为适度。

The data, presented on May 31, 2025, highlights the drug’s performance in targeting estrogen receptor-positive breast cancer. Vepdegestrant showed measurable benefits over existing therapies for certain patient groups but did not achieve significant breakthroughs in overall progression-free survival rates.

该数据于2025年5月31日发布，重点展示了该药物在靶向雌激素受体阳性乳腺癌中的表现。Vepdegestrant对某些患者群体相较于现有疗法显示出可衡量的益处，但在总体无进展生存率方面并未取得显著突破。

The study provides insights into both the potential applications and limitations of Protac-based drugs in oncology. Further analysis is expected to explore its efficacy across broader patient populations and refine its role within current treatment protocols..

该研究提供了基于Protac的药物在肿瘤学中潜在应用和局限性的见解。进一步的分析有望探索其在更广泛患者群体中的疗效，并完善其在当前治疗方案中的作用。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: May 31, 2025

日期：2025年5月31日

Versatile AI System from Cornell Detects Subtle Changes in Medical Imaging Series

康奈尔大学多功能人工智能系统检测医学影像序列中的细微变化

Reimagining Clinical Trials: Building Infrastructure for Made-to-Order Therapies

重新构想临床试验：为定制疗法构建基础设施

Mouse Study Identifies Intestinal Immune Cells as Potential Key to Preventing Food Allergies.